IL-17A-negative patients with RA showed lower MMP1/TIMP4 and MMP3/TIMP4 ratios in post anti-TNF-α therapy, which provided an initial clue for the diagnostic potential of TIMP4 for RA [21]. This evidence concerns the gene MMP1 and rheumatoid arthritis.